Leerink Partners Rates ARS Pharmaceuticals (SPRY) buy
Leerink Partners maintained its Outperform rating on ARS Pharmaceuticals with a $24.00 price target as shares change hands around $8.54, a 181.03% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Leerink Partners rated ARS Pharmaceuticals, Inc. ($SPRY) "buy" with a $24 price target on June 25, 2026.
Since the rating, $SPRY is up 6.7% after 1 week, down 28.2% after 1 month and down 49.9% to date (from the $8.02 close on Jun 25, 2026).
SPRY
ARS Pharmaceuticals, Inc.
Key Points
- Leerink Partners maintained its Outperform rating on ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY) with a $24.00 price target on June 25, 2026.
- Leerink Partners's $24 price target implies 181.03% upside from ARS Pharmaceuticals, Inc.'s ($SPRY) current $8.54 share price.
- The stock trades near $8.54, leaving a wide gap below the analyst's $24.00 price target and the broader analyst mean of $22.50.
- A group of six company insiders each acquired 30,000 shares on June 24, 2026, ahead of the analyst rating update.
Get $SPRY trade alerts by text
We text you when insiders, Congress or big funds trade $SPRY. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ARS Pharmaceuticals, Inc. alert may contain errors. Disclosures
Leerink Partners Maintains Outperform Rating on ARS Pharmaceuticals
On June 25, 2026, analyst Roanna Ruiz at Leerink Partners maintained an Outperform rating on ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY) while setting a price target of $24.00. The firm later updated its target to $18.00 on August 13, 2026. This evaluation arrives as the biotechnology firm continues developing treatments for severe allergic reactions, drawing attention from both Wall Street researchers and company insiders.
Leerink Partners vs. the S&P 500
Hypothetical returns from Leerink Partners's disclosed trades, not real profit or advice. How we model this.
Where the Stock Trades Versus the Target
Shares of ARS Pharmaceuticals change hands around $8.54, placing the market price well below the $24.00 target set during the June update. Across Wall Street, four analysts track the equity, producing a consensus recommendation of strong buy. Individual price targets span from a low of $15.00 up to a high of $30.00, with a mean price target resting at $22.50. The current share price sits not far from its 200-day moving average of $8.38, while having moved between a 52-week low of $4.07 and a peak of $13.15 over the past year.
$SPRY price target
ARS Pharmaceuticals, Inc. daily closes and this analyst's $24 target. Not advice.
Insider Buying and Selling at ARS Pharmaceuticals, Inc.
Ahead of the analyst update, multiple company leaders expanded their personal investments in the San Diego-based business. On June 24, 2026, Phillip Schneider, Pratik Shah, Saqib Islam, Brent Saunders, Laura Shawver, and Peter Thompson each acquired 30,000 shares in open market transactions. These concurrent purchases by six key figures highlight internal alignment within the organization.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc. is a biopharmaceutical enterprise focused on creating needle-free epinephrine options for emergency allergy care. Its primary product candidate, neffy, delivers treatment through an intranasal route to address severe Type I allergic reactions, including anaphylaxis. Founded in 2015, the firm employs 195 people in California.
What to Watch at ARS Pharmaceuticals, Inc.
Market participants will monitor the company's next earnings report scheduled for November 10, 2026, for further financial updates. Investors will also track whether the stock narrows the gap toward the $24.00 price target set by Leerink Partners as clinical and commercial milestones approach.
Related Filing Alerts
Source: Leerink Partners's rating change on $SPRY (Jun 25, 2026). Written by software, not financial advice. How we make alerts